Fundacion Centro Nacional De Investigaciones Oncologicas Carlos III

Glaxosmithkline Intellectual Property Development Limited

Fundacion Del Sector Publico Estatal Centro Nacional De Investigaciones Oncologicas Carlos III

Jose Ignacio Martín Hernando

Antonio Rodríguez Hergueta

Sonia Martínez González

Joaquin Pastor Fernández

Joaquín Pastor Fernández

Rosario Concepción Riesco Fagundo

Carmen Blanco Aparicio

Ana Belén García García

David Álvaro Cebrián Muñoz

Francisco Javier Ramos Lima

Rosa Maria Álvarez Escobar

Maria Luisa León Diaz

Rosa Maria Alvarez Escobar

Ana Maria Garcia Collazo

Ana Isabel Hernández Higueras

Maria Isabel Castellote Alvaro

Antonio Salgado Serrano

Carmen Blanco Aparicío

Beatriz Noya Marino

Esther Gonzalez Cantalapiedra

Carl-Gustave Pierre Saluste

Rosa María Álvarez Escobar

Cristina Ana Gómez De La Oliva

María Isabel Albarrán Santiño

Esther González Cantalapiedra

Elena Hernández Encinas

Joaquin Pastor Fernandez

Ana Belén GARCÍA GARCÍA

David ÁLvaro CEBRIÁN MUÑOZ

Rosa María ÁLvarez Escobar

Antonio Cebriá Gómez

The present invention relates to novel compounds or pharmaceutically acceptable salts thereof, corresponding compositions, and methods and/or uses in therapy, for example in the treatment of parasitic infections such as malaria, in particular infection by. 

Compounds for the treatment of parasitic infections

There is provided compounds of formula I, wherein R1, R, R, R, X, Y, Z, Rand ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds. 

Macrocyclic compounds as protein kinase inhibitors

There is provided compounds of formula (I), wherein R, R, Rand Rhave meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I). 

Tricyclic compounds for use as kinase inhibitors

There is provided compounds of formula (I), wherein A, A, A, A, B, B, B, B, B, B, B, Band Rhave meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. 

Inhibitors of PI3 kinase

Growing community of inventors

Madrid, Spain

Jose Ignacio Martín Hernando